Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays - PubMed (original) (raw)

. 2004 Dec 30;47(27):6658-61.

doi: 10.1021/jm049486a.

Francis Y Lee, Ping Chen, Derek Norris, Joel C Barrish, Kamelia Behnia, Stephen Castaneda, Lyndon A M Cornelius, Jagabandhu Das, Arthur M Doweyko, Craig Fairchild, John T Hunt, Ivan Inigo, Kathy Johnston, Amrita Kamath, David Kan, Herbert Klei, Punit Marathe, Suhong Pang, Russell Peterson, Sidney Pitt, Gary L Schieven, Robert J Schmidt, John Tokarski, Mei-Li Wen, John Wityak, Robert M Borzilleri

Affiliations

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays

Louis J Lombardo et al. J Med Chem. 2004.

Abstract

A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources